Clinical Trial

Patient-Derived Breast Cancer Organoids for Therapeutic Extracellular Vesicle Isolation (PDO-Mercurial01)

Study acronym: PDO-Mercurial
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this study is to establish organoid cultures, which are three-dimensional in vitro tumor models capable of supporting the long-term ex vivo growth of tumor cells derived from patients with breast carcinoma. These organoids will be used for the isolation of extracellular vesicles (EVs), which are naturally released by cells and have the ability to selectively recognize tumor tissue. Due to these properties, EVs represent promising vectors for the targeted delivery of diagnostic agents, with potential applications in fluorescence-guided surgery.
Trial Details
NCT Number NCT07421479
Lead Sponsor Istituti Clinici Scientifici Maugeri SpA
Conditions Invasive Breast Cancer
Enrollment 50 participants
Start Date 2025-01-01
Primary Completion 2027-10-28 (estimated)
Study Completion 2027-10-28 (estimated)
Updated on ClinicalTrials.gov 2026-02-19